Skip to main content

Table 2 Association between p53 mutations as analyzed by SSCP and DNA sequencing, p53 immunoreactivty and p53 status with clinicopathological features

From: Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards

Variable Patients No. p53 mutation (5-8 exons) No. (%) p53 nuclear reactivity No. (%) p53 status No. (%)
p53 mut p53 wt OR 95%CI Negative Positive P value altered Non- altered P value
       - +/- Total + ++ Total     
Total 29 11(37.9) 18(62.1)    6(20.7) 6(20.7) 12(41.4) 3(10.3) 14(48.3) 17(58.6)   21(72.4) 8(27.6)  
Grade                
Low(I&II) 14 5(35.7) 9(64.3) 1.2 0.26-5.4 4(28.6) 5(35.7) 9(64.3) 1(7.1) 4(28.6) 5(35.7) 0.02 7(50) 7(50) 0.01
High (III) 15 6(40) 9(60)    2(13.3) 1(6.7) 3(20) 2(13.3) 10(66.7) 12(80)   14(93.3) 1(6.9)  
Stage                
Low(Ta&T1) 14 5(35.7) 9(64.3) 1.2 0.26-5.4 4(28.6) 5(35.7) 9(64.3) 1(7.1) 4(28.6) 5(35.7) 0.02 7(50) 7(50) 0.01
High (T2) 15 6(40) 9(60)    2(13.3) 1(6.7) 3(20) 2(13.3) 10(66.7) 12(80)   14(93.3) 1(6.9)  
  1. Negative indicates that less than 10% of tumor nuclei demonstrated p53 immunoreactivty, positive; 10% or more of tumor nuclei demonstrated p53 immunoreactivty, p53 status; + has alteration (mutation, or immunoreactivty score +,++, or both), - no alteration (mutation (−) and IHC (score -, +/−) for p53), OR, Odds Ratio; CI, Confidence Intervals, P Value ≤ 0.05 or 0.01 (Fisher’s exact probability test).